Developer docs
API playgroundTry for free, no card

Search company profiles

Upperton Pharma Solutions

Full company profile

uuid0006d3g

Namestring
Upperton Pharma Solutions
Legal namestring
Upperton Limited
Websiteurl
upperton.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Upperton Pharma Solutions is a Nottingham, UK-based pharmaceutical Contract Development and Manufacturing Organisation (CDMO) founded in 1999 by Dr. Richard Johnson. The company operates an integrated single-site model from its 60,000 sqft Trent Gateway facility, providing end-to-end drug development services from pre-clinical feasibility through Phase III clinical supply and commercial manufacturing across oral solid, nasal, pulmonary, and parenteral dosage forms. Its technical differentiators include three proprietary platforms — UpperNose™ (nasal delivery), PulmoCraft™ (pulmonary/DPI delivery), and UpperSolv™ (early formulation screening) — built on more than 20 years of spray drying expertise, plus a purpose-built £7 million sterile fill-finish facility designed to revised EU GMP Annex 1 (2023) standards targeting the documented 12–18 month UK/EU small-scale aseptic capacity bottleneck.

The company is privately held, with significant development capital provided by mid-market private equity firm Inflexion in 2022 — alongside which headcount more than doubled from 40 to 90+ employees and a £20 million commercial-scale equipment investment was deployed at Trent Gateway. Revenue is generated through project-based, multi-year CDMO contracts covering formulation development, analytical services, GMP clinical manufacturing, scale-up, and regulatory affairs, with pricing negotiated per engagement. Its customer base consists of emerging biotech companies and mid-sized pharmaceutical firms, particularly those developing nasal, pulmonary, and bioavailability-enhanced products requiring integrated R&D-to-GMP transitions. The company maintains MHRA GMP approval, Home Office Schedule 1–4 controlled drugs approval, and EU GMP Annex 1 (2023) design compliance, with the March 2026 MHRA licence application for the sterile facility representing the most recent regulatory milestone.

Upperton's go-to-market combines high-touch enterprise sales (under Executive Leadership Team oversight, with a dedicated commercial team led by a Chief Commercial Officer appointed in April 2025) with event-driven demand generation at major industry conferences (CPHI, DCAT, BioSpain, DDL) and content-led thought leadership via whitepapers, webinars, and an insights blog. The company has received multiple industry awards including the 2023 King's Award for Enterprise in International Trade, 2024 and 2025 Pharma Industry Awards UK honours, 2025 CDMO Leadership Awards (Europe and International), and consecutive Sunday Times Best Places to Work recognition (2025, 2026), as well as a #73 ranking in the Sunday Times 100 fastest-growing private UK companies in 2024.

Short descriptiontext

Upperton Pharma Solutions is a Nottingham-based integrated pharmaceutical CDMO offering formulation development, GMP manufacturing, and sterile fill-finish services across oral, nasal, pulmonary, and parenteral dosage forms for emerging biotech and mid-sized pharma clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBeeston, United Kingdom
HQ citystring
Beeston
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical development, CDMO manufacturing services, sterile fill-finish manufacturing, nasal pulmonary drug delivery, pharmaceutical formulation development
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO (Contract Development and Manufacturing Services)
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Contract Development and Manufacturing (CDMO) Services
TypeProfessional Services
Description

Upperton generates revenue through long-term contractual partnerships for integrated drug development and manufacturing services spanning formulation development, analytical services, GMP clinical manufacturing, scale-up, and regulatory support. Revenue is project-based, typically structured around specific drug development programs from pre-clinical through Phase III and potentially commercial supply.

upperton.com
2Clinical Manufacturing Supply
TypeOne Time License
Description

Manufacturing and supply of clinical trial materials (Phase I-III) including tablets, capsules, dry powder inhalers, nasal suspensions, and parenteral products under GMP conditions. Billed per batch/project with pricing dependent on dosage form complexity, batch size, and regulatory requirements.

upperton.com
3Analytical and QC Services
TypeProfessional Services
Description

Dedicated analytical testing services including method development, validation, QC release testing, and stability studies. Provided as part of integrated CDMO programs or as standalone services.

upperton.com
4Sterile Fill-Finish Manufacturing
TypeOne Time License
Description

Purpose-built sterile manufacturing facility (£7 million investment) offering aseptic fill-finish services for vials and pre-filled syringes (up to 2,000 units per batch), targeting emerging biotech companies addressing the 12-18 month capacity constraint in the UK/EU sterile CDMO market.

upperton.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Integrated CDMO Services - bespoke project pricing
ModelOtherBilling cadenceMulti-year contract
Notes

No standard pricing tiers disclosed publicly. Services are quoted on a project-by-project basis, typically covering formulation development, analytical development, GMP manufacturing, and regulatory support across pre-clinical to Phase III stages.

upperton.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1UpperNose™
Description

A unique nasal product development platform for liquid and dry powder formulations supporting local delivery, systemic delivery, and direct nose-to-brain delivery.

upperton.com
+3 more records
Core offering1 text field

Upperton Pharma Solutions is an integrated pharmaceutical Contract Development and Manufacturing Organisation (CDMO) providing end-to-end drug development and manufacturing services from a single site in Nottingham, UK. The company offers formulation development, analytical services, GMP clinical manufacturing (Phase I-III), scale-up and technology transfer, sterile fill-finish, and regulatory submission support across oral solid, nasal, pulmonary, and parenteral dosage forms. It serves emerging biotech and mid-sized pharmaceutical companies requiring integrated R&D-to-GMP transitions, leveraging proprietary delivery platforms (UpperNose™, PulmoCraft™, UpperSolv™) and over 20 years of spray drying expertise.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Rapid product introduction within 4-6 weeks
+4 more records
Product overview1 text field

Upperton Pharma Solutions is an integrated CDMO (Contract Development and Manufacturing Organisation) offering end-to-end pharmaceutical development and manufacturing services from a single site. The company operates as a unified platform with interconnected services: Formulation Development and UpperSolv™ (early formulation screening) feed into Pharmaceutical Spray Drying and the UpperNose™ (nasal) and PulmoCraft™ (pulmonary) development platforms. These feed into Clinical Manufacturing with capabilities across Oral Solid Dosage Forms, Sterile Fill/Finish, and analytical/QC services. Scale-Up and Tech Transfer, Registration Activities, Regulatory Affairs Support, and Project Management round out the services. All operations are conducted at the Trent Gateway facility in Nottingham, UK, supporting customers from pre-clinical through Phase III and commercial manufacturing.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1VaxHub / University of Oxford's Pandemic Sciences Institute
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Upperton Pharma Solutions was awarded a VaxHub Sustainable Grant to advance oral vaccine delivery in partnership with the University of Oxford's Pandemic Sciences Institute. The collaboration focuses on developing oral vaccine delivery formulations, leveraging Upperton's spray drying and formulation expertise.

upperton.com
2EU Horizon 2020 Grant Consortium
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Upperton's participation in the EU Horizon 2020 Grant consortium in 2014 marked a pivotal milestone. Collaborative efforts aimed at developing nasal and oral HIV vaccines utilizing spray drying technology, underscoring the company's commitment to innovation and collaboration.

upperton.com
Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight10 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Portugal-headquartered CDMO with deep expertise in spray drying, particle engineering, and inhalation drug delivery. Hovione is a directly comparable specialized CDMO with overlapping capabilities in the very niche areas (spray drying, nasal, pulmonary) where Upperton has built its proprietary platforms.

2Recipharm
TypeBroad incumbent
Description

Large European CDMO offering formulation, manufacturing, and analytical services across oral, sterile, inhalation, and other dosage forms. Recipharm competes for similar biotech and pharma customers but at greater scale and with broader capabilities than Upperton's specialized platform.

TypeBroad incumbent
Description

Global CRO/CDMO offering formulation development, manufacturing, and analytical services across multiple modalities. Pharmaron is a broader incumbent serving similar biotech and pharma customers but with significantly greater scale and global footprint than Upperton.

TypeDirect peer
Description

UK-based integrated CDMO offering formulation development, clinical manufacturing, and drug product services across multiple dosage forms. Quotient Sciences and Upperton directly compete for the same emerging biotech and mid-pharma customers needing integrated pre-clinical to clinical supply, with significant overlap in COO Lorna Patrick's prior experience.

TypeDirect peer
Description

UK-based sterile fill-finish CDMO specializing in small-batch aseptic manufacturing for clinical trials. Symbiosis directly competes with Upperton's new sterile facility in the same UK small-scale aseptic manufacturing market segment addressing biotech capacity constraints.

TypeDirect peer
Description

UK-headquartered CDMO offering API development, formulation, and GMP manufacturing services. Sterling competes in the same UK CDMO market with overlapping capabilities in oral solid dosage and analytical services for biotech and pharma customers.

TypeDirect peer
Description

European CDMO providing formulation development and GMP manufacturing services for oral solid and sterile dosage forms. Aesica (where Upperton's Director of Clinical Manufacturing previously worked) operates in the same UK/EU market segment serving emerging biotech customers.

TypeDirect peer
Description

UK-based pharmaceutical CDMO offering sterile and non-sterile manufacturing, formulation development, and analytical services. Nova Laboratories competes with Upperton in UK-based CDMO services for clinical supply manufacturing (where Upperton's Director of Clinical Manufacturing Paul Kelsall previously worked).

TypeDirect peer
Description

India-headquartered integrated CDMO offering formulation development, API, and drug product manufacturing services. Sai Life Sciences competes with Upperton for global biotech customers seeking integrated CDMO partnerships with mid-tier cost structures.

TypeDirect peer
Description

UK-based CDMO providing API development, formulation, and GMP manufacturing services. Onyx Scientific operates in the same UK market segment with similar customer targeting of small-to-mid biotech and pharma companies requiring integrated CDMO services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Upperton Pharma Solutions

Pharmaceutical CDMO (Contract Development and Manufacturing Services)upperton.com

Upperton Pharma Solutions is a Nottingham-based integrated pharmaceutical CDMO offering formulation development, GMP manufacturing, and sterile fill-finish services across oral, nasal, pulmonary, and parenteral dosage forms for emerging biotech and mid-sized pharma clients.

What Upperton Pharma Solutions does

Upperton Pharma Solutions is a Nottingham, UK-based pharmaceutical Contract Development and Manufacturing Organisation (CDMO) founded in 1999 by Dr. Richard Johnson. The company operates an integrated single-site model from its 60,000 sqft Trent Gateway facility, providing end-to-end drug development services from pre-clinical feasibility through Phase III clinical supply and commercial manufacturing across oral solid, nasal, pulmonary, and parenteral dosage forms. Its technical differentiators include three proprietary platforms — UpperNose™ (nasal delivery), PulmoCraft™ (pulmonary/DPI delivery), and UpperSolv™ (early formulation screening) — built on more than 20 years of spray drying expertise, plus a purpose-built £7 million sterile fill-finish facility designed to revised EU GMP Annex 1 (2023) standards targeting the documented 12–18 month UK/EU small-scale aseptic capacity bottleneck.

The company is privately held, with significant development capital provided by mid-market private equity firm Inflexion in 2022 — alongside which headcount more than doubled from 40 to 90+ employees and a £20 million commercial-scale equipment investment was deployed at Trent Gateway. Revenue is generated through project-based, multi-year CDMO contracts covering formulation development, analytical services, GMP clinical manufacturing, scale-up, and regulatory affairs, with pricing negotiated per engagement. Its customer base consists of emerging biotech companies and mid-sized pharmaceutical firms, particularly those developing nasal, pulmonary, and bioavailability-enhanced products requiring integrated R&D-to-GMP transitions. The company maintains MHRA GMP approval, Home Office Schedule 1–4 controlled drugs approval, and EU GMP Annex 1 (2023) design compliance, with the March 2026 MHRA licence application for the sterile facility representing the most recent regulatory milestone.

Upperton's go-to-market combines high-touch enterprise sales (under Executive Leadership Team oversight, with a dedicated commercial team led by a Chief Commercial Officer appointed in April 2025) with event-driven demand generation at major industry conferences (CPHI, DCAT, BioSpain, DDL) and content-led thought leadership via whitepapers, webinars, and an insights blog. The company has received multiple industry awards including the 2023 King's Award for Enterprise in International Trade, 2024 and 2025 Pharma Industry Awards UK honours, 2025 CDMO Leadership Awards (Europe and International), and consecutive Sunday Times Best Places to Work recognition (2025, 2026), as well as a #73 ranking in the Sunday Times 100 fastest-growing private UK companies in 2024.

Upperton Pharma Solutions firmographics

Firmographics
Name
Upperton Pharma Solutions
Legal name
Upperton Limited
Website
https://upperton.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
101–250 employees
Short description
Upperton Pharma Solutions is a Nottingham-based integrated pharmaceutical CDMO offering formulation development, GMP manufacturing, and sterile fill-finish services across oral, nasal, pulmonary, and parenteral dosage forms for emerging biotech and mid-sized pharma clients.
Ownership category
akta.pro rank

Upperton Pharma Solutions industry classification

Industry
Product category
Pharmaceutical CDMO (Contract Development and Manufacturing Services)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Contract pharmaceutical development
  • CDMO manufacturing services
  • Sterile fill-finish manufacturing
  • Nasal pulmonary drug delivery
  • Pharmaceutical formulation development

Where Upperton Pharma Solutions is headquartered

Location

Headquarters

HQ city
Beeston
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Upperton Pharma Solutions business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Contract Development and Manufacturing (CDMO) Services: Upperton generates revenue through long-term contractual partnerships for integrated drug development and manufacturing services spanning formulation development, analytical services, GMP clinical manufacturing, scale-up, and regulatory support. Revenue is project-based, typically structured around specific drug development programs from pre-clinical through Phase III and potentially commercial supply.
  2. Clinical Manufacturing Supply: Manufacturing and supply of clinical trial materials (Phase I-III) including tablets, capsules, dry powder inhalers, nasal suspensions, and parenteral products under GMP conditions. Billed per batch/project with pricing dependent on dosage form complexity, batch size, and regulatory requirements.
  3. Analytical and QC Services: Dedicated analytical testing services including method development, validation, QC release testing, and stability studies. Provided as part of integrated CDMO programs or as standalone services.
  4. Sterile Fill-Finish Manufacturing: Purpose-built sterile manufacturing facility (£7 million investment) offering aseptic fill-finish services for vials and pre-filled syringes (up to 2,000 units per batch), targeting emerging biotech companies addressing the 12-18 month capacity constraint in the UK/EU sterile CDMO market.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractIntegrated CDMO Services - bespoke project pricing

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Upperton Pharma Solutions product offering

Product offering

Core offering

Upperton Pharma Solutions is an integrated pharmaceutical Contract Development and Manufacturing Organisation (CDMO) providing end-to-end drug development and manufacturing services from a single site in Nottingham, UK. The company offers formulation development, analytical services, GMP clinical manufacturing (Phase I-III), scale-up and technology transfer, sterile fill-finish, and regulatory submission support across oral solid, nasal, pulmonary, and parenteral dosage forms. It serves emerging biotech and mid-sized pharmaceutical companies requiring integrated R&D-to-GMP transitions, leveraging proprietary delivery platforms (UpperNose™, PulmoCraft™, UpperSolv™) and over 20 years of spray drying expertise.

Product overview

Upperton Pharma Solutions is an integrated CDMO (Contract Development and Manufacturing Organisation) offering end-to-end pharmaceutical development and manufacturing services from a single site. The company operates as a unified platform with interconnected services: Formulation Development and UpperSolv™ (early formulation screening) feed into Pharmaceutical Spray Drying and the UpperNose™ (nasal) and PulmoCraft™ (pulmonary) development platforms. These feed into Clinical Manufacturing with capabilities across Oral Solid Dosage Forms, Sterile Fill/Finish, and analytical/QC services. Scale-Up and Tech Transfer, Registration Activities, Regulatory Affairs Support, and Project Management round out the services. All operations are conducted at the Trent Gateway facility in Nottingham, UK, supporting customers from pre-clinical through Phase III and commercial manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

  • UpperNose™: A unique nasal product development platform for liquid and dry powder formulations supporting local delivery, systemic delivery, and direct nose-to-brain delivery.
  • PulmoCraft™
  • UpperSolv™
  • UpperDry™

Quantifiable outcome

  • Rapid product introduction within 4-6 weeks
  • +4 more outcomes

Companies that use Upperton Pharma Solutions

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Upperton Pharma Solutions technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Upperton Pharma Solutions partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and minor.

  • VaxHub / University of Oxford's Pandemic Sciences InstitutecoreStrategic or Co-development Partner · 1 January 2025Upperton Pharma Solutions was awarded a VaxHub Sustainable Grant to advance oral vaccine delivery in partnership with the University of Oxford's Pandemic Sciences Institute. The collaboration focuses on developing oral vaccine delivery formulations, leveraging Upperton's spray drying and formulation expertise.
  • EU Horizon 2020 Grant ConsortiumminorStrategic or Co-development Partner · 1 January 2014Upperton's participation in the EU Horizon 2020 Grant consortium in 2014 marked a pivotal milestone. Collaborative efforts aimed at developing nasal and oral HIV vaccines utilizing spray drying technology, underscoring the company's commitment to innovation and collaboration.

Scale indicators11 records

Recent moves11 records

Expansion highlights10 records

Upperton Pharma Solutions competitors and assessment

Company assessment

Direct peers

  • Hovione: Portugal-headquartered CDMO with deep expertise in spray drying, particle engineering, and inhalation drug delivery. Hovione is a directly comparable specialized CDMO with overlapping capabilities in the very niche areas (spray drying, nasal, pulmonary) where Upperton has built its proprietary platforms.
  • Quotient Sciences: UK-based integrated CDMO offering formulation development, clinical manufacturing, and drug product services across multiple dosage forms. Quotient Sciences and Upperton directly compete for the same emerging biotech and mid-pharma customers needing integrated pre-clinical to clinical supply, with significant overlap in COO Lorna Patrick's prior experience.
  • Symbiosis Pharmaceutical Services: UK-based sterile fill-finish CDMO specializing in small-batch aseptic manufacturing for clinical trials. Symbiosis directly competes with Upperton's new sterile facility in the same UK small-scale aseptic manufacturing market segment addressing biotech capacity constraints.
  • Sterling Pharma Solutions: UK-headquartered CDMO offering API development, formulation, and GMP manufacturing services. Sterling competes in the same UK CDMO market with overlapping capabilities in oral solid dosage and analytical services for biotech and pharma customers.
  • Aesica Pharmaceuticals: European CDMO providing formulation development and GMP manufacturing services for oral solid and sterile dosage forms. Aesica (where Upperton's Director of Clinical Manufacturing previously worked) operates in the same UK/EU market segment serving emerging biotech customers.
  • Nova Laboratories: UK-based pharmaceutical CDMO offering sterile and non-sterile manufacturing, formulation development, and analytical services. Nova Laboratories competes with Upperton in UK-based CDMO services for clinical supply manufacturing (where Upperton's Director of Clinical Manufacturing Paul Kelsall previously worked).
  • Sai Life Sciences: India-headquartered integrated CDMO offering formulation development, API, and drug product manufacturing services. Sai Life Sciences competes with Upperton for global biotech customers seeking integrated CDMO partnerships with mid-tier cost structures.
  • Onyx Scientific: UK-based CDMO providing API development, formulation, and GMP manufacturing services. Onyx Scientific operates in the same UK market segment with similar customer targeting of small-to-mid biotech and pharma companies requiring integrated CDMO services.

Broad incumbents

  • Recipharm: Large European CDMO offering formulation, manufacturing, and analytical services across oral, sterile, inhalation, and other dosage forms. Recipharm competes for similar biotech and pharma customers but at greater scale and with broader capabilities than Upperton's specialized platform.
  • Pharmaron: Global CRO/CDMO offering formulation development, manufacturing, and analytical services across multiple modalities. Pharmaron is a broader incumbent serving similar biotech and pharma customers but with significantly greater scale and global footprint than Upperton.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Upperton Pharma Solutions social profiles

Digital presence

Upperton Pharma Solutions compliance and trust

Trust signal

Compliance3 records

Upperton Pharma Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Upperton Pharma Solutions leadership team

Management profile

Number of profiles

Upperton Pharma Solutions funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Upperton Pharma Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Upperton Pharma Solutions

What does Upperton Pharma Solutions do?

Upperton Pharma Solutions is an integrated pharmaceutical Contract Development and Manufacturing Organisation (CDMO) providing end-to-end drug development and manufacturing services from a single site in Nottingham, UK. The company offers formulation development, analytical services, GMP clinical manufacturing (Phase I-III), scale-up and technology transfer, sterile fill-finish, and regulatory submission support across oral solid, nasal, pulmonary, and parenteral dosage forms. It serves emerging biotech and mid-sized pharmaceutical companies requiring integrated R&D-to-GMP transitions, leveraging proprietary delivery platforms (UpperNose™, PulmoCraft™, UpperSolv™) and over 20 years of spray drying expertise.

Is Upperton Pharma Solutions a public or private company?

Upperton Pharma Solutions is a private company. It is classified as private equity controlled and is currently operating.

When was Upperton Pharma Solutions founded?

Upperton Pharma Solutions was founded in 1999. It employs 101 to 250 people.

Where is Upperton Pharma Solutions based?

Upperton Pharma Solutions is headquartered in Beeston, United Kingdom, in the Europe region.

How does Upperton Pharma Solutions make money?

Four revenue lines are on record. Contract Development and Manufacturing (CDMO) Services are the primary driver. The others are clinical Manufacturing Supply, analytical and QC Services and sterile Fill-Finish Manufacturing.

Who are Upperton Pharma Solutions's main competitors?

Direct peers on record are Hovione, Quotient Sciences, Symbiosis Pharmaceutical Services, Sterling Pharma Solutions, Aesica Pharmaceuticals, Nova Laboratories, Sai Life Sciences and Onyx Scientific. Broad incumbents are Recipharm and Pharmaron.

Does Upperton Pharma Solutions have an API?

No public API is recorded for Upperton Pharma Solutions.

What industry is Upperton Pharma Solutions in?

Upperton Pharma Solutions's product category is Pharmaceutical CDMO (Contract Development and Manufacturing Services). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceUpperton Submits MHRA Licence Application for Annex 1 Sterile Manufacturing Facility Following APS Validation.Upperton Pharma Solutions has submitted its licence application to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for approval of its new £7 million, 7,000 sq. ft sterile manufacturing facility in Nottingham, following successful aseptic process simulation validation completed under the revised EU GMP Annex 1 (2023) framework. The facility is among the first UK contract development and manufacturing organisations to submit under the revised Annex 1 requirements, targeting early-phase sterile manufacturing for small and mid-sized biopharma innovators with batch sizes up to 2,000 units. The company stated the investment directly addresses known capacity constraints in the UK and EU sterile fill-finish market, where lead times commonly reach 12 to 18 months, and the facility includes infrastructure for future aseptic spray-drying operations expected in Q4 2026.PharmiWeb.comUpperton Advances Sterile Manufacturing Facility with MHRA SubmissionUpperton Pharma Solutions has submitted its application to the UK MHRA for approval of its new 7,000 sq. ft sterile manufacturing facility in Nottingham, following successful completion of aseptic process simulation validation batches under revised EU GMP Annex 1 (2023) requirements. The £7 million investment is designed to address a critical bottleneck in the sterile CDMO sector, where lack of small-scale aseptic manufacturing capacity creates delays of 12-18 months for emerging biopharma companies. Upperton claims to be among the first UK CDMOs with a facility specifically designed to comply with the new regulatory framework, supporting formulation development and clinical manufacturing for parenteral, nasal, and pulmonary drug delivery products.ContractpharmaThe Evolution of Biotech and CDMO Partnerships: A 2026 OutlookThe author argues that the biotech industry has shifted from quick-to-clinic asset sales to pursuing full development pipelines, requiring CDMOs to evolve from service providers to strategic partners capable of supporting projects from early development through commercialization. The article emphasizes that CDMO selection is now a critical business decision for biotechs, where operational agility, technical expertise, and collaborative culture matter more than capability alone. The author, CEO of Upperton Pharma Solutions, positions effective CDMO partnerships as essential for navigating the complex transition from R&D to GMP manufacturing.PharmiWeb.comUpperton Pharma Solutions Advancing Oral Vaccines Delivery with Oxford’s Pandemic Sciences InstituteUpperton Pharma Solutions received a grant from the VaxHub Sustainable Platform Funding Call to develop an oral formulation for Adenovirus-vectored vaccines with the University of Oxford. The project, led by Professor Dame Sarah Gilbert, aims to enable needle-free delivery and is expected to complete in summer 2026.PharmiWeb.comUpperton completes build of new £7m sterile manufacturing facility.Upperton Pharma Solutions completed a new 7,000 sq ft sterile manufacturing facility in Nottingham, UK, designed to EU GMP Annex-1 standards. The facility supports aseptic and terminally sterilised small volume liquids and powders for parenteral, nasal, and pulmonary delivery, with batch sizes up to 2,000 vials. Commissioning and validation are ongoing.ContractpharmaUpperton Invests £5M in New Sterile Manufacturing FacilityUpperton Pharma Solutions invested £5 million to expand its Trent Gateway site with a 7,000 sq-ft sterile manufacturing facility. Construction begins this February and is expected to complete in early 4Q24. The facility will use VHP isolation technology for GMP fill-finish of sterile drug products.ContractpharmaUpperton Pharma Solutions Investment Increases Tabletting CapabilitiesUpperton Pharma Solutions invested in a new Futorque X tablet press to expand its tabletting capabilities for R&D and production. The machine can produce up to 130,000 tablets per hour and follows MHRA approval for its GMP clinical facility. The investment aims to support clients' clinical manufacturing and scale-up needs.